Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks